Who Pays Travel and Medical Costs in an Alzheimer’s Clinical Trial?

Clinical trials don't erase health care costs, but clear policies—and your own questions—can minimize financial surprises.

The answer is straightforward: responsibility is shared and depends on the type of cost and where the trial gets its funding. In an Alzheimer’s clinical trial, the trial sponsor typically pays for investigational drugs and protocol-required medical tests. Government-funded trials via Medicaid must cover routine patient care costs.

Participants or their insurance may cover certain expenses, though many trials reimburse travel and parking. If you’re considering enrolling in an Alzheimer’s trial, knowing who pays what can mean the difference between a manageable commitment and financial strain that forces you to withdraw. For a concrete example: If you enroll in a Phase III Alzheimer’s drug trial at a major medical center, the sponsor covers the experimental medication (often $10,000–$20,000 per month), all required brain imaging and blood work, and your travel reimbursement to the site. But if your local neurologist orders additional bloodwork unrelated to the trial protocol, or if you develop a side effect requiring urgent care at an out-of-network hospital, responsibility becomes murky and depends on trial agreements and your insurance.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Official resources:

Table of Contents

Who Actually Pays for Travel and Medical Expenses in Alzheimer’s Trials?

The responsibility falls on multiple parties depending on what is being paid. The trial sponsor—the pharmaceutical company, research institution, or government agency running the study—bears the cost of the investigational drug itself and all medical procedures directly required by the trial protocol. This includes neuropsychological testing, PET scans, lumbar punctures, genetic testing, and routine blood draws mandated by the study. These costs can run $5,000 to $20,000 or more per month per participant.

Travel costs and inconvenience payments have a different funding stream. The FDA explicitly permits sponsors to reimburse participants for actual out-of-pocket travel expenses—airfare, parking, lodging, and meals—without triggering concerns about “undue influence” on enrollment decisions. However, not all sponsors reimburse equally. Some cover the full cost; others offer partial reimbursement or a flat daily stipend. Your insurance may cover routine medical care received at in-network providers, though many trial sites are specialized research centers not in your plan’s network.

What the Trial Sponsor Must Cover

Trial sponsors have a legal obligation to cover the cost of investigational medications and all procedures that are part of the protocol. An investigational Alzheimer’s drug that hasn’t been approved by the FDA won’t be covered by Medicare, Medicaid, or private insurance—only the sponsor covers it. Similarly, protocol-required diagnostic testing (MRI scans, cerebrospinal fluid analysis, cognitive assessments performed by the research team) falls squarely on the sponsor, not on you or your insurance. Where sponsors sometimes resist paying is for medical care outside the strict protocol.

If you develop a side effect—say, a rash or headaches—and your own doctor treats it, the sponsor may claim it’s a pre-existing condition or unrelated to the trial. This is why having a clear, written trial agreement is critical. The best-practice standard, endorsed by research institutions, is that sponsors should cover reasonable and customary costs of diagnosing and treating any adverse events that occur during trial participation, whether or not they’re formally attributed to the drug. In practice, however, some sponsors dispute these bills or require participants to file claims with their primary insurance first.

Medicaid’s Mandatory Coverage of Routine Care in Trials

Since January 2022, all state Medicaid programs have been required to cover routine patient care costs for participants in clinical trials that receive funding or approval from the NIH, CDC, Agency for Healthcare Research and Quality, Department of Defense, Department of Veterans Affairs, or CMS. This is a significant protection for low-income participants. The coverage applies regardless of whether the trial site is out of state or out of your plan’s network—Medicaid cannot deny coverage on those grounds. However, this mandatory coverage has a major exclusion: it does not cover the investigational drug or service being tested.

If the trial’s experimental Alzheimer’s treatment isn’t yet approved and wouldn’t normally be covered by Medicaid, Medicaid still won’t pay for it. Only the trial sponsor does. Routine care—blood tests, imaging, office visits with neurologists—yes. The experimental drug itself—no. This distinction is important because it means even Medicaid participants aren’t fully insulated from cost confusion.

What Travel and Participation Costs Can Be Reimbursed?

The FDA’s guidance permits reimbursement for a wider range of expenses than many people assume. Sponsors can reimburse actual costs for travel (airfare or mileage), parking, lodging near the trial site, meals during travel days, and even reasonable childcare or dependent care needed to attend visits. Some trials also offer “inconvenience payments”—compensation for your time, effort, discomfort, and the burden of repeated visits—separate from reimbursement. The catch is that reimbursement policies vary dramatically by trial.

Some richly funded pharmaceutical trials reimburse every expense in full. NIH-funded trials, particularly those conducted at the NIH Clinical Center, often provide travel support and reimburse lodging. Smaller or under-resourced trials may offer only a small daily stipend or no reimbursement at all. Institutional Review Boards (IRBs)—the ethics committees that oversee human research—must review and approve all compensation before the trial starts, ensuring it’s reasonable and not so generous that it coerces people into participating. You should ask the research coordinator upfront: What is reimbursed? What’s not? Is there a cap?.

The Real Financial Burden Many Participants Face

Despite all these policies and funding streams, the data shows that financial hardship from trial participation is real and common. A 2024–2025 study of cancer trial participants found that 47% reported experiencing trial-related financial hardship, and the proportion is likely similar for dementia trials since Alzheimer’s trials also require frequent travel to specialized sites. Travel expenses accounted for 71% of reported hardship, followed by medical bills (58%), dining (40%), and housing costs (40%). In the same study, 58% of participants received no reimbursement despite incurring costs.

Average out-of-pocket spending per trial visit ranged from $100 to $1,000, and some participants spent more than $25,000 across their entire trial participation. These numbers reveal a critical gap: even when trials reimburse, the reimbursement often arrives weeks or months later, forcing participants to float expenses upfront. And “reimbursement” typically only covers documented, pre-approved costs; spontaneous expenses—a missed meal, unexpected parking, gas for an extra trip—often aren’t reimbursed. For participants on fixed incomes or with limited savings, this can be prohibitively burdensome.

If you suffer a treatment-related injury or adverse event during an Alzheimer’s trial, the sponsor’s obligation to pay for treatment depends on the language in the trial agreement. Best-practice standards, endorsed by clinical research organizations, hold that sponsors should bear the cost of medical diagnosis and treatment for protocol-induced injuries or adverse events. But “best practice” is not always legally binding. Some trial agreements specify that the sponsor will cover such costs; others place responsibility on the participant’s insurance or leave it ambiguous.

Before enrolling, ask: “If I develop a serious side effect, who pays for its treatment?” and request a written answer. If the trial site is at an academic medical center, they usually have clearer policies and more willingness to cover trial-related harm. If it’s a smaller or private research facility, they may push costs back to insurance or the participant. This is worth clarifying in writing because you don’t want to discover ambiguity after an adverse event occurs.

Steps to Take Before Enrolling to Understand Your Financial Obligations

Ask the research team or coordinator for a complete, itemized breakdown of who pays for what. Request it in writing if possible. Specifically ask: What are the investigational drug costs? What medical tests and procedures does the sponsor cover? Are there limits on how many visits or tests get covered? What travel and meal reimbursements are provided, and when do you receive them? If you have Medicaid, ask whether the trial meets the January 2022 mandatory coverage criteria. If you have Medicare or private insurance, ask whether the trial site is in-network and how your insurer handles experimental treatments. Review the informed consent document carefully—it should detail compensation and cost responsibility.

If it doesn’t, ask for clarification. Contact your insurance company directly (not through the trial site) to ask what they will and won’t cover. Ask whether there’s a participant advocate or ombudsman at the trial site who can help navigate billing disputes. And if the trial seems prohibitively expensive despite reimbursement policies, it’s reasonable to decline. Financial strain is a legitimate reason not to enroll, and trials depend on honest participant engagement to produce reliable data.

  • —

You Might Also Like

Browse more: Activities | Alzheimer’s | Aphasia | Blog/News | Books

Related Posts